Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01959243 · ClinicalTrials.gov registry record · Phase 3
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 507
- Enrollment target
NCT01959243 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 507 participants.
The verdict
NCT01959243, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 507 participants
- Enrollment target
Study Summary
To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
Interventions
- DRUG Vehicle
- DRUG Brimonidine Tartrate
- DRUG Sodium Fluorescein
- DRUG Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2014-02-22 |
| Est. Completion | 2014-06-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01959243
The ClinicalTrials.gov registry entry for NCT01959243 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT01959243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01959243 about?
NCT01959243 is a clinical study titled "Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants". To compare the safety and tolerability of brimonidine tartrate ophthalmic solution 0.025% versus its vehicle in a population of pediatric, adult, and geriatric participants. At least 51% of participants will be 40 years of age or older.
What is the current status of trial NCT01959243?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 507 participants. The study started on 2014-02-22. Estimated completion is 2014-06-23.
What interventions are being tested in trial NCT01959243?
The interventions under investigation include: Vehicle (DRUG), Brimonidine Tartrate (DRUG), Sodium Fluorescein (DRUG), Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP (DRUG).
Who is sponsoring clinical trial NCT01959243?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.